Upbeat Comments from Lilly’s president Dr. John Lechleiter about Zyprexa and Cymbalta:
“Regarding Zyprexa, Lechleiter stated, "2006 marked a turning point for Zyprexa in the U.S. Measured by the four-week moving average of total prescription share, by retail volume or by hospital share, Zyprexa sales in the
Lechleiter also had comments about Cymbalta, which were paraphrased as “Cymbalta is expected to be a key driver of growth for Lilly in 2007. In 2006, Cymbalta outperformed all branded antidepressants in the
My View: Well, that’s nice that Cymbalta prescriptions are running wild, even in the absence of any consistent data that it actually reduces pain in depressed patients (which is its unique marketing angle), and that Zyprexa sales are doing well. In the irony department, Byetta, Lilly’s diabetes drug is also doing well. In an era of atypical antipsychotics, of course, we would expect drugs like Byetta to really shine. The SOHO study (very hip name for a drug study) is fresh and I’ve not yet read it, but to discuss the CATIE results as if they were positive for Zyprexa is misleading at best.